Key Highlights
- Shares were trading down 18.66% at $9.88, from a prior close of $12.14.
- Third quarter net sales were $1.6 billion, down 9%, and operating EBITDA was $222 million, down 17%.
- Latin America Organic Sales fell 31%, while North America, EMEA and Asia Pacific all grew.
- The 2026 operating EBITDA outlook was cut to $1.1 billion to $1.125 billion from about $1.3 billion.
- Management said a third-party cost review is under way and that cost actions will be needed.
Corteva (NYSE:CTVA) shares were trading down 18.66% at $9.88 today, from a prior close of $12.14, after the crop protection company reported third quarter results and cut its 2026 profit outlook. It was Corteva's first Earnings Call as a standalone company, and management pointed to a sharp deterioration in Brazil.
Brazil Overwhelms Growth Elsewhere
Third quarter net sales were $1.6 billion, down 9% on both a reported and organic basis. Operating EBITDA was $222 million, down 17%, with a Margin of 14%, down 140 basis points. Price was the largest headwind at roughly $120 million, with about 90% of that tied to acetochlor in the U.S. and generic pressure in Brazil.
Latin America organic sales fell 31%, with Volume down 24% and price down 7%. Sales in the region were down about $220 million, more than offsetting roughly $70 million of growth elsewhere.
CEO Luke Kissam said Brazil conditions worsened sharply in the final weeks of the quarter. He said part of the problem was specific to Corteva, because too much product sold into the channel last year had not reached the farm.
Other Regions and New Products Hold Up
North America sales rose 7% on volume growth of 19%, even as pricing fell 12% because of acetochlor. EMEA grew 12%, or 14% organically, and Asia Pacific grew 3%, or 5% organically. New product volumes rose 20% in the quarter, with growth in every region.
Outlook Cut and Cost Review
Corteva now expects 2026 operating EBITDA of $1.1 billion to $1.125 billion, compared with about $1.3 billion estimated at its September Investor Day. That implies a decline of about 12% at the midpoint, with a margin near 15%. The company estimated a full-year EBITDA impact of about $100 million from elevated Brazil channel inventory and is not assuming meaningful improvement in purchasing there this year. Fourth quarter EBITDA is expected to be about half of last year's level on a pro forma basis, and operating EPS is guided at $0.76 to $0.80.
Management has started work with a third party to examine its cost structure and said cost actions will need to be taken. Asked about cost opportunities, the CEO said everything is on the table, including whether certain products or countries should be exited.
Acetochlor Pricing and Brazil Inventory Set the Next Test
Management expects acetochlor price pressure in the fourth quarter to be similar to the third, tapering in the first half of 2027. It expects Brazil inventory to reach a more acceptable level by the end of the local growing season, though that will weigh on fourth quarter results. Peer FMC (NYSE:FMC) is trading down 7.70%. Fourth quarter results, the pace of Brazil channel inventory clearing and the outcome of the cost review are the next markers.

_11_20_2026_12_17_14_767368.jpg)




Please wait processing your request...